[1]张炜浩,郭 志,李保国,等.CT导向下125I粒子植入补救治疗盆腔恶性肿瘤近期疗效评价[J].介入放射学杂志,2013,(04):308-311.
 ZHANG Wei? hao,GUO Zhi,LI Bao? guo,et al.CT- guided radioactive seeds 125I implantation used as salvage therapy for malignant pelvic tumors: evaluation of short- term effects[J].J Intervent Med,2013,(04):308-311.
点击复制

CT导向下125I粒子植入补救治疗盆腔恶性肿瘤近期疗效评价()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2013年04期
页码:
308-311
栏目:
非血管介入
出版日期:
2013-04-17

文章信息/Info

Title:
CT- guided radioactive seeds 125I implantation used as salvage therapy for malignant pelvic tumors: evaluation of short- term effects
作者:
张炜浩;  郭 志;  李保国;  于海鹏;  司同国;  倪 虹;  姚艳红
Author(s):
ZHANG Wei?蛳 hao;  GUO Zhi;  LI Bao?蛳 guo;  YU Hai?蛳 peng;  SI Tong?蛳 guo;  NI Hong;  YAO Yan?蛳 hong.
Department of Interventional Therapy, Affiliated Tumor Hospital of Tianjin Medical University, Tianjin Municipal Key Laboratory of Cancer Prevention and Treatment, Tianjin 300060, China
关键词:
【关键词】 盆腔恶性肿瘤;  补救治疗;  125I粒子;  近期疗效
文献标志码:
A
摘要:
【摘要】 目的 评价CT导向下125I粒子植入补救治疗盆腔恶性肿瘤的近期临床疗效及安全性。方法 32例盆腔恶性肿瘤,可评价病灶35处,肿瘤长径为3 ~ 12 cm,平均(6.8 ± 2.3)cm。所有病例均为接受过手术、化疗或放疗等综合治疗后盆腔复发或转移的恶性肿瘤患者,术前应用治疗计划系统(TPS)计算布源,在CT导向下将125I粒子植入盆腔病灶内,随访观察临床受益率、疼痛缓解率、生活质量评分及并发症状况。结果 术后随访2个月,随访结束评价病灶完全缓解(CR)4/35,部分缓解(PR)20/35,病灶稳定(SD)6/35,病灶进展(PD)5/35,临床受益率(CR + PR + SD)85.7%(30/35),疼痛缓解率89.3%(25/28),总体生活质量较治疗前有明显改善(P < 0.001)。近期不良反应轻微,未见大出血、盆腔脓肿、肠瘘、肠穿孔等严重并发症。结论 CT导向下125I粒子植入补救治疗盆腔恶性肿瘤安全有效、操作简便、创伤小、近期临床受益率高,可作为一种改善患者生活质量、降低肿瘤负荷的高效局部治疗手段。

参考文献/References:

[1] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45: 228 ?蛳 247.[2] Bonomi AE, Cella DF, Hahn EA, et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of Life measurement system[J]. Qual Life Res, 1996, 5: 309 ?蛳 320.[3] Chase DM, Huang HQ, Wenzel L, et al. Quality of Life and survival in advanced cervical Cancer: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2012, 125: 315 ?蛳 319.[4] Bouchard P, Efron J. Management of recurrent rectal cancer[J]. Ann Surg Oncol, 2010, 17: 1343 ?蛳 1356.[5] 范卫君, 张 亮, 张福君, 等. CT导向下125I粒子植入治疗复发性盆腔恶性肿瘤[J]. 中国微创外科杂志, 2007, 7: 127 ?蛳 129.[6] Park RI, Liberman FZ, Lee DJ, et al. Iodine?蛳 125 seed implantation as an adjunct to surgery in advanced recurrent squamous cell Cancer of the head and neck[J]. Laryngoscope, 1991, 101: 405 ?蛳 410.[7] Cosset JM, Flam T, Thiounn N, et al. Brachytherapy for prostate Cancer: old concept, new techniques[J]. Bull Cancer, 2006, 93: 761 ?蛳 766.[8] Wang J, Jiang Y, Li J, et al. Intraoperative ultrasound?蛳 guided iodine?蛳 125 seed implantation for unresectable pancreatic carcinoma[J]. J Exp Clin Cancer Res, 2009, 28: 88.[9] Nag S, Dehaan M, Scruggs G, et al. Long?蛳 term follow?蛳 up of patients of intrahepatic malignancies treated with iodine?蛳 125 brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2006, 64: 736 ?蛳 744.[10] Sharma SK, Forgione H, Isaacs JH. Iodine?蛳 125 interstitial implants as salvage therapy for recurrent gynecologic malignancies[J]. Cancer, 1991, 67: 2467 ?蛳 2471.[11] Wang Z, Lu J, Liu L, et al. Clinical application of CT?蛳 guided (125)I seed interstitial implantation for local recurrent rectal carcinoma[J]. Radiat Oncol, 2011, 6: 138.[12] Wang JJ, Yuan HS, Li JN, et al. CT?蛳 guided radioactive seed implantation for recurrent rectal carcinoma after multiple therapy[J]. Med Oncol, 2010, 27: 421 ?蛳 429.[13] Van Lonkhuijzen L, Thomas G. Palliative radiotherapy for cervical carcinoma, a systematic review[J]. Radiother Oncol, 2011, 98: 287 ?蛳 291.[14] Stone NN, Stock RG. Long?蛳 term urinary, sexual, and rectal morbidity in patients treated with iodine?蛳 125 prostate brachytherapy followed up for a minimum of 5 years[J]. Urology, 2007, 69: 338 ?蛳 342.

备注/Memo

备注/Memo:
(收稿日期:2012-11-30)
更新日期/Last Update: